IP Library Granted Patent US 9,631,175
Granted Patent B2
US 9,631,175 · App. 14/329,510 · Granted Apr 25, 2017

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

Inventors: Michel Revel (Rechovot, IL); Judith Chebath (Rechovot, IL); Michal Izrael (Rechovot, IL); Rosalia Kaufman (Rechovot, IL)
Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
C12N5/0622A61K35/30C12N5/0619G01N33/5058C12N2501/11C12N2501/115C12N2501/155C12N2501/385C12N2501/41C12N2506/02C12N2533/52C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,631,175
App. No.
14/329,510
Granted
Apr 25, 2017
Kind
B2
Abstract

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Claims (7)

1. A method of enhancing myelination in the CNS of a subject, the method comprising directly administering at a site within the CNS of a subject in need thereof a therapeutically effective amount of an isolated oligodendrocyte or astrocyte, thereby enhancing myelination at the site of administration, wherein the isolated oligodendrocyte or astrocyte is generated by:

(a) culturing in suspension human embryonic stem cells in the presence of retinoic acid and epidermal growth factor (EGF) to generate neurospheres;

(b) contacting said neurospheres with EGF and bFGF on an adherent substrate, wherein said adherent substrate comprises an extracellular matrix component; and

(c) contacting said neurospheres following step (b), wherein said neurospheres are intact or dissociated, with a medium comprising noggin, said medium being devoid of EGF and bFGF, thereby generating the oligodendrocyte or astrocyte.

2. The method of claim 1 , wherein the subject suffers from a medical condition selected from the group consisting of autoimmune diseases, Guillan-Barre syndrome or congenital leukodystrophies, adrenoleukodystrophies, Pelizaeus-Merzbacher, Charcot-Marie-Tooth, Krabbe or Alexander disease, vanishing white matter syndrome, progressive multifocal leukoencephalopathy, infectious demyelinating diseases, postinflammatory demyelinated lesions, neurodegenerative diseases, multisystem degeneration, vascular diseases, ischemic white matter damage, vascular leukoencephalopathies, subcortical infarcts, brain trauma, spinal cord trauma, demyelinative injury, neoplasms and oligodendrio-glioma.

3. The method of claim 1 , wherein said cells comprise oligodendrocytes and the subject suffers from insufficient myelination.

4. The method of claim 1 , wherein said cells comprise astrocytes and the subject suffers from a medical condition selected from the group consisting of Alexander disease, epilepsy, Alzheimer's disease, spinal cord injury, traumatic brain injury and neurogenesis deficiencies.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2020
From: REVEL, MICHEL; CHEBATH, JUDITH; IZRAEL, MICHAL; KAUFMAN, ROSALIA
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 054298/0092 →
Continuity (3)
Continuation 12310495
Provisional Application 60840426 · Aug 28, 2006
Related Publication 20140322179A1 · Oct 30, 2014